© Getty Images

CPHI North America 2024

Piramal Pharma unveils expanded services and growth vision

By Isabel Cameron

What is ADC specialist Piramal Pharma planning for the upcoming CPHI North America conference? We sat down with chief commercial officer Stuart Needleman to find out what's on the company's agenda.

© Getty Images

ADC licensing deals reached peak of $16.6 billion in 2022

By Isabel Cameron

The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.

© Getty Images

SOTIO expands ADC pipeline with Synaffix tie up

By Isabel Cameron

Synaffix, a Lonza company commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has entered a licensing agreement with SOTIO, a clinical stage immuno-oncology company owned by PPF Group.


Samsung Ventures invests in Araris Biotech in emerging ADC strategy

By Jonathan Smith

Samsung Ventures, the global investment arm of Samsung Group, has invested an undisclosed amount in the Swiss company Araris Biotech. The deal is independent from Araris’ ongoing Series A fundraising and will be used to bankroll the development of antibody-drug...


Merck picks up another ADC agreement

By Ben Hargreaves

With speculation that Merck is lining up a multi-billion dollar acquisition in the ADC space, the company has agreed a second collaboration deal with Sichuan Kelun Pharmaceutical.